Physician profile
James E Owens
NPI 1063492528
$432,541.21
in general payments reported to CMS, 2019-2025
16 companies · $89K in 2025
The $89K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $8,579 · 2021: $40K · 2022: $44K · 2023: $98K · 2024: $124K · 2025: $89K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $247K · Consulting Fee: $32K · Travel and Lodging: $14K · Honoraria: $12K · Food and Beverage: $5,477 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $247,339.75 |
| Consulting Fee | $31,960.00 |
| Travel and Lodging | $13,684.80 |
| Honoraria | $11,925.00 |
| Food and Beverage | $5,476.70 |
| Education | $152.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $138,941.21 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $124,418.39 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $74,107.63 | 2021-2025 | Lybalvi, Aristada |
| Janssen Pharmaceuticals, INC | $45,122.92 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Axsome Therapeutics, INC. | $39,782.39 | 2024-2025 | Auvelity |
| Allergan, INC. | $9,034.67 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $405.14 | 2022-2025 | Caplyta |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $239.24 | 2023 | Rexulti |
| Supernus Pharmaceuticals, INC. | $122.05 | 2023 | Qelbree |
| Ironshore Pharmaceuticals INC. | $88.25 | 2019-2020 | |
| Lundbeck LLC | $85.04 | 2022-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $66.18 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $54.70 | 2019 | |
| Jazz Pharmaceuticals INC. | $35.50 | 2019 | |
| Vanda Pharmaceuticals INC. | $20.32 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $17.58 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Owens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.